Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

298.76 -14.03 (-4.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
22 23 Next >
News headline image
Peering Into Alnylam Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Nvidia, Affirm Holdings, Carnival Corp, Alnylam Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗
On Monday, major U.S. indices showed mixed performance. The Dow Jones Industrial Average closed up by nearly 0.7% at 39,411.21, 
Via Benzinga
Topics Stocks
News headline image
Semiconductor, Nvidia Woes Deepen; Nasdaq 100 Slips, Dow Rallies; Bitcoin Sinks To $60,400: What's Driving Markets Monday? ↗
Wall Street faces a continuation of last week’s trend during Monday’s morning trading, with semiconductor stocks selling off heavily and dragging down the tech sector, while the broader market remains... 
Via Benzinga
Topics Stocks
News headline image
Behind the Scenes of Alnylam Pharmaceuticals's Latest Options Trends ↗
 
Via Benzinga
News headline image
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears ↗
A 2024 coffee recall is in effect for products made by Snapchill LLC due to concerns of botulism from the FDA for hundreds of canned coffees. 
Via InvestorPlace
News headline image
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success ↗
The challenge for Alnylam now will be to find and diagnose patients with the condition known as ATTR-CM, which is considered rare. 
Via InvestorPlace
News headline image
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge ↗
Alnylam Pharmaceuticals reports positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy. The trial showed significant reductions in mortality and... 
Via Benzinga
News headline image
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug ↗
The companies are working on treatments for ATTR amyloidosis with cardiomyopathy. 
Via Investor's Business Daily
News headline image
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Alnylam Pharmaceuticals? ↗
 
Via Benzinga
News headline image
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Masters In Trading - Saturday, June 22 ↗
In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio. 
Via Talk Markets
News headline image
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge ↗
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Alnylam Issues 2023 Corporate Responsibility Report
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
ALNY Stock Earnings: Alnylam Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗
ALNY stock results show that Alnylam Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data ↗
The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood... 
Via Benzinga
News headline image
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks to Buy on the Dip: March 2024 ↗
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three. 
Via InvestorPlace
News headline image
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years ↗
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.